Skip to main content Accessibility help
×
Home

Extended-Spectrum β-Lactamase Producers Reported as Susceptible to Piperacillin-Tazobactam, Cefepime, and Cefuroxime in the Era of Lowered Breakpoints and No Confirmatory Tests

  • Dror Marchaim (a1), Bharath Sunkara (a1), Paul R. Lephart (a1), Uma Mahesh Gudur (a1), Ashish Bhargava (a1), Ryan P. Mynatt (a1), Jing J. Zhao (a1), Suchitha Bheemreddy (a1), Kayoko Hayakawa (a1), Teena Chopra (a1), Sorabh Dhar (a1) and Keith S. Kaye (a1)...

Abstract

  • An abstract is not available for this content so a preview has been provided below. Please use the Get access link above for information on how to access this content.

Copyright

Corresponding author

Division of Infectious Diseases, 5 Hudson, Harper University Hospital, 3990 John R. Street, Detroit, MI 48201 (drormc@hotmail.com)

References

Hide All
1.Schwaber, MJ, Carmeli, Y. Mortality and delay in effective therapy associated with extended-spectrum β-lactamase production in Enterobacteriaceae bacteraemia: a systematic review and metaanalysis. J Antimicrob Chemother 2007;60(5): 913920.
2.Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Susceptibility Testing: Nineteenth Informational Supplement. Approved standard M100-S19. Wayne, PA: CLSI, 2009.
3.Paterson, DL, Ko, WC, Von Gottberg, A, et al. Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended-spectrum ß-lactamases. Clin Infect Dis 2004;39(1):3137.
4.Paterson, DL, Bonomo, RA. Extended-spectrum β-lactamases: a clinical update. Clin Microbiol Rev 2005;18(4): 657686.
5.Rodriguez-Bano, J, Navarro, MD, Retamar, P, Picon, E, Pascual, A. β-Lactam/β-lactam inhibitor combinations for the treatment of bacteremia due to extended-spectrum β-lactamase-producing Escherichia coli: a post hoc analysis of prospective cohorts. Clin Infect Dis 2012;54(2): 167174.
6.Clinical and Laboratory Standards Institute (CLSI). CLSIM100-S20 (2010) Cephalosporin and Aztreonam Breakpoint Revisions Fact Sheet. Wayne, PA: CLSI, 2010.
7.Jenkins, SG. Rationale Supporting CLSI Changes to Interpretive Criteria (Breakpoints) for Several Cephalosporines and Aztreonam When Testing Enterobacteriaceae. Washington, DC: American Society for Microbiology, 2010:14.
8.Rodriguez-Bano, J, Picon, E, Navarro, MD, Lopez-Cerero, L, Pascual, A. Impact of changes in CLSI and EUCAST breakpoints for susceptibility in bloodstream infections due to extended-spectrum β-lactamase-producing Escherichia coli. Clin Microbiol Infect doi:10.1111/j.l469-0691.2011.03673.x. Published September 13, 2011.
9.de Oliveira, KR, de Freitas, AL, Willers, DM, Barth, AL, Zavascki, AP. High frequency of β-lactam susceptibility in CTX-M-type extended-spectrum-β-lactamase-producing Klebsiella pneumoniae, Escherichia coli and Proteus mirabilis according to the new CLSI recommendations. J Antimicrob Chemother 2010;65(11): 24812483.
10.Ambrose, PG, Bhavnani, SM, Jones, RN. Pharmacokinetics-pharmacodynamics of cefepime and piperacillin-tazobactam against Escherichia coli and Klebsiella pneumoniae strains producing extended-spectrum β-lactamases: report from the ARREST program. Antimicrob Agents Chemother 2003;47(5): 16431646.
11.Perez, F, Bonomo, RA. Can we really use β-lactam/β-lactam inhibitor combinations for the treatment of infections caused by extended-spectrum β-lactamase-producing bacteria? Clin Infect Dis 2012;54(2): 175177.

Extended-Spectrum β-Lactamase Producers Reported as Susceptible to Piperacillin-Tazobactam, Cefepime, and Cefuroxime in the Era of Lowered Breakpoints and No Confirmatory Tests

  • Dror Marchaim (a1), Bharath Sunkara (a1), Paul R. Lephart (a1), Uma Mahesh Gudur (a1), Ashish Bhargava (a1), Ryan P. Mynatt (a1), Jing J. Zhao (a1), Suchitha Bheemreddy (a1), Kayoko Hayakawa (a1), Teena Chopra (a1), Sorabh Dhar (a1) and Keith S. Kaye (a1)...

Metrics

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed